Phase 2 zenagamtide trial meets A1C and body weight endpoints in type 2 diabetes
- In 262 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor, once-weekly subcutaneous zenagamtide met the primary endpoint of change in A1C across all doses versus placebo after 36 weeks and the key supportive secondary endpoint of body weight change with doses 1.5 mg and greater.
- At 40 mg, zenagamtide cut A1C by up to 1.71 percentage points from a 7.8% baseline, with up to 89.1% achieving A1C below 7% and up to 76.2% at or below 6.5%.
- Zenagamtide also reduced body weight by up to 14.6% at week 36 with the 40 mg dose. Novo Nordisk plans to initiate a phase 3 development program in H2 2026.